Title |
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
|
---|---|
Published in |
BMC Cancer, January 2018
|
DOI | 10.1186/s12885-017-3916-y |
Pubmed ID | |
Authors |
Ming Li, Anqi Li, Shuling Zhou, Yan Xu, Yaoxing Xiao, Rui Bi, Wentao Yang |
Abstract |
Programmed cell death ligand 1 (PD-L1) is a potential predictive biomarker of the response to anti-PD-L1/anti- programmed cell death 1 (PD-1) therapy in multiple cancers, including triple negative breast cancer(TNBC). The purpose of this study was to investigate whether PD-L1 expression is homogenous in primary tumors(PTs) and synchronous axillary lymph node metastases(LNMs) of TNBC. PD-L1 expression was immunohistochemically evaluated in 101 TNBC patients' PTs and paired LNMs. PD-L1 expression in tumor cells and infiltrating immune cells or node lymphocytes in the PTs and associated LNMs was scored separately and was correlated with patients' clinical parameters and prognoses. PD-L1 expression exhibited spatial heterogeneity in both the tumor cells and the infiltrating immune cells or node lymphocytes of PTs and LNMs. The PD-L1 expression levels were significantly higher in the lymphocytes and tumor cells of the LNMs than in the PTs. PD-L1 expression was also more frequent among the LNMs. PD-L1 expression was associated with high grade and more stromal tumor-infiltrating lymphocytes(TILs). Furthermore, the disease-free survival and overall survival were similar between the PT- negative/LNM- positive and PT- positive/LNM- positive patients, both of which exhibited worse disease-free survival(DFS) thanPT -negative/LNM -negative patients. The differential expression of PD-L1 between the PTs and LNMs suggests that LNMs PD-L1 status may be used to indicate whether PD-1/PD-L1-targeted therapy would be suitable for a node-positive TNBC patient in the future. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 88 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 8% |
Researcher | 7 | 8% |
Student > Master | 7 | 8% |
Student > Doctoral Student | 7 | 8% |
Student > Bachelor | 7 | 8% |
Other | 17 | 19% |
Unknown | 36 | 41% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 30% |
Biochemistry, Genetics and Molecular Biology | 6 | 7% |
Agricultural and Biological Sciences | 4 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Immunology and Microbiology | 3 | 3% |
Other | 6 | 7% |
Unknown | 40 | 45% |